A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Part of paid clinical trials in Hemet, California.

Sponsor
Vor Biopharma
Study ID
NCT06456567
Phase
PHASE3
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Telitacicept — BIOLOGICAL
    Subcutaneous injection
  • Placebo — DRUG
    Subcutaneous injection

Study Details

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.

Key Dates

Start date
Sep 30, 2024
Status verified
Jan 2026
Primary completion
Jan 2, 2025
Completion
Jan 6, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Telitacicept
    Telitacicept + Standard of Care (SOC)
  • Placebo Comparator: Placebo
    Placebo + Standard of Care (SOC)

Primary Outcome Measure

SLE Responder Index (SRI-4) [ Time Frame: Week 52 ]

Locations (4)

FacilityCityStateZIPSite coordinators
Hemet siteHemetCalifornia92543-
Menifee siteMenifeeCalifornia92586-
Rockford siteRockfordIllinois61114-
Stafford siteStaffordTexas77477-

Find similar trials in Hemet, CA

By condition
Lupus (SLE)
By specialty
RheumatologyAutoimmune disease
By research site
Hemet site· Hemet, CAMenifee site· Menifee, CARockford site· Rockford, ILStafford site· Stafford, TX

Related Studies